Seegene, Inc. and Randox Laboratories today announced that they have entered into an agreement in which Randox will obtain a non-exclusive license to Seegene's Dual Priming Oligo (DPO™) technology to develop high-throughput diagnostic screening panels capable of simultaneously detecting a wide variety of infectious pathogens that cause either respiratory or sexually transmitted diseases.

See press releases about this article: click here